Straits Times Index
3,283.26 -4.49 (-0.14%) Nikkei
37,929.07 +300.59 (+0.80%) Hang Seng
17,702.15 +417.61 (+2.42%) FTSE 100
8,078.86 +38.48 (+0.48%) Bitcoin USD
64,552.98 +329.76 (+0.51%) CMC Crypto 200
1,389.17 -7.36 (-0.53%)
Achilles Therapeutics plc (ACHL)
After hours:
| Previous close | 0.7895 |
| Open | 0.7977 |
| Bid | 0.7225 x 100 |
| Ask | 0.8020 x 100 |
| Day's range | 0.7400 - 0.8000 |
| 52-week range | 0.7400 - 1.7600 |
| Volume | |
| Avg. volume | 771,359 |
| Market cap | 32.134M |
| Beta (5Y monthly) | 1.09 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.7400 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.83 |
GlobeNewswireAchilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – Strong cash position of $131.5 million supports operations through 2025 – LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company d
- GlobeNewswire
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
– Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – First three patients dosed in CHIRON and THETIS with enhanced host chemo-conditioning, along with IL-2 aligned to standard TIL therapy, show improved cNeT persistence and engraftment – LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company
Simply Wall St.Will Achilles Therapeutics (NASDAQ:ACHL) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
